Inspire Medical price target lowered to $150 from $270 at Lake Street

Lake Street lowered the firm’s price target on Inspire Medical (INSP) to $150 from $270 and keeps a Buy rating on the shares after revenue and EPS guidance were reduced as a result of slower than anticipated Inspire V launch. The Inspire V launch faced transitional headwinds that drove a reset to 2025 expectations, but “the foundational work now appears largely complete” and the firm thinks shares will offer “an attractive risk/reward as the transitory headwinds abate and growth reaccelerates,” the analyst tells investors.